SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.94-3.7%12:02 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Young who wrote (9582)11/25/2003 11:09:02 PM
From: Biomaven   of 52153
 
Michael,

Existing surfactant (animal derived and the inferior synthetic) sales are not great - likely under $100m, although this compound will doubtless expand the market some. So I'm not looking for huge appreciation even if it is approved for this indication.

However, there is the very real possibility that DSCO's product will work also in ARDS (adult respiratory distress syndrome) and perhaps even in severe asthma (and maybe also in SARS, although the thought of bronchial lavage on a SARS patient is very scary). Either ARDS or asthma would send the stock through the roof.

Here is some asthma discussion:

respiratory-research.com

And here is a research report on DSCO (a little dated but still worth reading):

bristoldirect.com

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News